Clot in Medical Technology

Heparin Use Prior to Endoscopic Vein Harvest Improves Graft Patency in Off-Pump Coronary Artery Bypass Patients

... Pre-heparinization Limits clot Retention and Decreases Residual clot Volume SAN FRANCISCO, June 8 /PRNewswire/ ... reduction in the incidence and volume of residual clot strands within the vein. In EVH, a small ...

March 2009 Mayo Clinic Health Letter Highlights Knee Repair Surgery, Anxiety Disorder and Preventing Blood Clots

... or surgery is more likely to trigger clot formation than flying. The March issue of ... affected by DVT or a pulmonary embolism, where a clot breaks away and blocks the lung artery -- often a ... for deep vein thrombosis seeks to prevent the clot from becoming bigger and to reduce the risk of ...

Research Highlights New Approaches to Prevent Blood Clots in Several High-Risk Patient Populations Including Largest Study Ever to Examine Use of Blood-Thinning Medication in Patients With Cancer

... Usually, the body naturally dissolves the clot when the injury has healed; however, when a clot does not dissolve naturally, it can become ... dangerous. Deep-vein thrombosis, a type of blood clot that typically forms in a major vein of the leg, ...

Trellis(R) Peripheral Infusion System Removes Blood Clots in Largest Reported Prospective Endovascular DVT (Deep Vein Thrombosis) Patient Series

... Clara, CA) successfully breaks up the blood clot in most patients in about 20 minutes. ... of care, which does not break up the existing clot but simply prevents further clot from forming. Alan M. Dietzek, MD, Chief of ...

Pivotal National Trial Uses Newest Interventional Radiology Treatment to Bust Blood Clots in Legs

... in patients with DVT (the formation of a blood clot in a leg vein). PTS, a common ... paradigm to one that includes interventional clot removal as an essential element of standard DVT ... the strong potential of interventional radiology clot removal treatments for DVT to improve public ...

Trellis(R) Catheter Removes Blood Clots Quickly, Restoring Blood Flow in 771 Deep Vein Thrombosis (DVT) Patients

... Clara, CA) successfully breaks up the blood clot in most patients in about 20 minutes. This ... restoration of patency in patients with acute clot was achieved in 97% of cases. The vast majority ... the Trellis catheter is our ability to get the clot out and have the patients able to walk away ...

New Deep Vein Thrombosis (DVT) Registry Data Show Clot Quickly Removed, Blood Flow Restored in Large Patient Registry

... with the Trellis device breaks up a blood clot in most patients much quicker than using a drug ... imaging, the device is guided directly to the clot via a catheter in the vein. DVT occurs when the ... in the vein. The Trellis device removes the blood clot and restores blood flow much quicker than the ...

CRESTOR(R) Reduced Risk of Blood Clots in the Veins

... a serious and sometimes fatal condition, occurs when a blood clot forms in a vein. The most common form of VTE is deep vein thrombosis ... 'deep veins' usually in the legs or pelvis. An embolism is created if the clot travels through the venous system. Blood clots lodging in the lungs are ...

Stents Can Treat - Not Just Prevent - Strokes, Suggests Early Research

... clot-busting drugs to the blockage through the veins or directly into the clot through an artery, or by removing the clot with a tiny corkscrew-like device or vacuuming it out. But early research ...

APTA Supports Surgeon General's 'Call to Action' to Prevent Deep Vein Thrombosis and Pulmonary Embolism

... estimated 10 percent of passengers on long flights may develop a DVT(2). A clot in the legs may dislodge and travel to the lungs, called pulmonary ... keep excess blood from remaining in the leg veins, helping to prevent clot formation," says Scherer. Physical therapists also suggest that when you ...

Analysis of Earlier European Stroke Trial Supports Treatment Regimen for Viprinex(TM) in Current International Phase 3 Clinical Trials

... ability to participate in blood clot formation, which should limit clot growth and reduce odds of reocclusion due to new clots. -- Reducing ... brain affected by the stroke. -- Indirectly activating the natural blood clot dissolving mechanism, which should restore blood flow further to areas of ...

Concentric Medical to Sponsor Randomized Trial

... /PRNewswire/ -- Concentric Medical, Inc., the global leader in devices for clot removal in ischemic stroke patients, today announced its plan to sponsor a ... returns to its original shape when deployed in and around the blood clot in the brain. About Concentric Medical Concentric Medical is located ...

Study Shows That Low-Molecular Weight Heparin (LMWH) was Associated with Reduced Hospital Costs of Venous Thromboembolism (VTE) Treatment Compared with Unfractionated Heparin (UFH)

... is a general term used to describe the formation of a blood clot (thrombus) that blocks a vein. This may occur in any part of the venous ... or other low-molecular-weight heparins are at risk of developing a blood clot in or around the spine. This condition may result in long-term or ...

Addition of INTEGRILIN(R) (Eptifibatide) to Bivalirudin Plus Standard of Care Inhibits Platelet Aggregation in Patients Undergoing Elective Coronary Stenting

... Thrombelastography measured the characteristics of maximum platelet-fibrin clot strength and time to initial platelet-clot formation. Clinical outcomes ... collagen (p<0.01 for all). Platelet reactivity and maximum platelet-fibrin clot strength were higher in patients with myocardial infarction. This is the ...

Study Results Show That Minimally Invasive Therapy is Successful for Over Two-Thirds of Stroke Patients Treated Outside the Standard Eight-Hour Window

... whose first angiography (a diagnostic test that infuses the blood vessels with dye in order to clearly visualize the vessel structures) confirming a clot in the brain was performed later than eight hours from the last time the patient was seen well. All patients were identified from prospectively ...

ThromboGenics and BioInvent Start Recruitment of Second 100 Patient Cohort in Phase II DVT Prophylaxis Study With TB-402

... with ThromboGenics and the exciting potential of this product candidate." About Deep Vein Thrombosis (DVT) DVT is caused when a blood clot forms in a deep vein, most commonly in the deep veins of the lower leg. DVT is a major public health issue and it is estimated that in the U.S. ...

Value of Genetic Testing for Preventing Blood Clots Unproven, According to New AHRQ Study

... to achieve its full potential," said AHRQ Director Carolyn M. Clancy, M.D. "But people can help reduce their likelihood of developing a blood clot by talking with their doctor about precautions." The evidence report was requested and supported by the Office of Public Health Genomics ...

New Analysis Evaluated Impact of Genetic Variation on Response to Prasugrel

... when the arteries become narrowed or clogged by cholesterol and fat deposits and cannot supply enough blood to the heart. In some cases, a blood clot may partially or totally block the blood supply to the heart resulting in ACS.(6) Many ACS patients are managed with PCI, which usually includes a ...

AHRQ-Funded Study Finds Lower Risk of Death and Heart Attack in Patients With Drug-Coated Stent Implants Compared to Those With Bare Metal Stents

... approved two stents coated with drugs in 2003 and 2004, but then issued precautionary advisories in 2006 after receiving scattered reports of blood clot formation, or thrombosis, and deaths. Subsequent clinical trials and other studies produced conflicting results. The researchers in the ...

Abbott Advances Its Revolutionary Fully Bioabsorbable Drug Eluting Stent With Initiation of Next Phase of Clinical Trial

... without being restricted by a permanent implant - indicating that the device was absorbed. In addition, there were no cases of thrombosis (blood clot formation) out to two years of follow-up, and no new major adverse cardiac events (MACE) between six months and two years, with the bioabsorbable ...

The Lancet Publishes Two-Year Results of Abbott's Fully Bioabsorbable Drug Eluting Stent

... , the first phase of the ABSORB trial demonstrated the following key results: A zero percent rate of stent thrombosis (blood clot formation) for all patients out to two years of follow up. No new major adverse cardiac events (MACE) between six months and two years. At ...

Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study

... of death. Platelets are activated at the site of atherosclerotic plaque rupture in arteries and release substances that initiate aggregation and clot formation, and thrombin is the most potent activator of platelets. Drugs that block platelet activation by other mechanisms, such as the thromboxane- ...

CSL Behring Receives Orphan-Drug Exclusivity for RiaSTAP(TM), First and Only Approved Treatment of Acute Bleeding Episodes in Patients with Congenital Fibrinogen Deficiency

... and hypofibrinogenemia. Approval was based on a pivotal phase II prospective, open-label pharmacokinetic (PK) and safety study using maximum clot firmness as a surrogate endpoint for hemostatic efficacy. "As a leader in developing safe, effective and high-quality biologic therapies, CSL ...

For Old or Young Dialysis Patients, AV Fistulas Remain Pure Gold

... explained Forauer. A significant number of patients with chronic kidney failure receive dialysis using synthetic bridge grafts that tend to clot or malfunction, decreasing reliable access for life-sustaining dialysis and causing considerable morbidity, discomfort and inconvenience for dialysis ...

New Study Using Combination of Bioengineered Skin and Stem Cells Shows Promise in Treatment of Non-Healing Wounds

... in humans prior to the research pioneered by Dr. Falanga and his team. Fibrin is a chemical by-product that occurs naturally in the body and helps clot blood. For each of the three scleroderma patients, up to three spray applications of stem cells were performed. "For the first time in humans, ...

Beating Blood Clots after Joint Replacement

... Even with a thorough pre-surgical evaluation, some patients are at higher risk for DVT than others having: A previous blood clot A family history of blood clots A genetic predisposition to blood clots, such as protein-deficient Preventing a DVT is ...

American Heart Association EMS Survey Uncovers Deficiencies in Response, Treatment and Transfer of Patients With Most Deadly Heart Attacks

... of Cardiology/American Heart Association guidelines, primary PCI, typically balloon angioplasty with stenting, is the preferred treatment over clot busting drugs if it can be achieved within 90 minutes. EMS is a critical part of the system of care to decrease time to treatment for STEMI ....

Inspiration Biopharmaceuticals, Inc. Initiates Phase 1 Clinical Trial of IB1001 for the Treatment of Hemophilia B

... inherited bleeding disorder caused by low levels or absence of a protein called a clotting factor, essential for blood clotting. This inability to clot results from an error in a person's genetic code, and occurs in approximately 1 in 10,000 male births. It is estimated that over 400,000 people ...

Portable CT Increases Chance of Stroke Survival and Recovery

... death in the U.S., and more than 700,000 cases of stroke are diagnosed annually. The most common kind of stroke, ischemic stroke, occurs when a blood clot blocks a blood vessel in the brain. Such strokes can be treated with thrombolytic therapy using a drug called tPA that dissolves the blockage. ...

Do You Know You're Having a Stroke?

... What you should know Strokes can happen quickly or can occur over several hours, with the condition continually worsening. The thrombus or clot that is causing the stroke can frequently be dissolved or disintegrated so blood can again flow to the brain. In such cases, immediate treatment can ...

Dronedarone (Multaq(R)) Reduced the Incidence and Duration of Hospitalization in Patients with Atrial Fibrillation

... are related to managing the arrhythmia itself and to the prevention of thromboembolism (obstruction of a blood vessel caused by fragments of a blood clot carried from the site of origin to obstruct another vessel). Atrial fibrillation may be treated with medications which either slow the heart rate or ...

American Heart Association Scientific Statement: Heart Patients Should Be Screened, Treated for Depression

... also possible that biological changes associated with depression such as reduced heart rate variability and increases in blood factors that encourage clot formation could increase risk, the statement said. Other recommendations in the statement include: -- Patients who have depressive symptoms ...

Surgeon General's 'Call to Action' to Prevent DVT/PE Praised by NATT as Turning Point

... of thousands of deaths and DVT/PEs that occur each year." In cooperation with the Centers for Disease Control, NATT will be convening "Stop the clot Forums" for patient and consumer education: -- October 4 - Minneapolis, MN http://www.stoptheclot.org/Trifold_self-mail_wForm_v1-2.pdf -- ...

Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel

... the arteries become narrowed or clogged by cholesterol and fat deposits and cannot supply enough blood to the heart. In some cases, a blood clot may partially or totally block the blood supply to the heart resulting in ACS.(7) Many ACS patients are managed with PCI, which usually includes a ...

Head-to-Head Study Showed Prasugrel Statistically Superior to Clopidogrel in Reducing Recurrent Cardiovascular Events

... when the arteries become narrowed or clogged by cholesterol and fat deposits and cannot supply enough blood to the heart. In some cases, a blood clot may partially or totally block the blood supply to the heart resulting in ACS.(4) Many ACS patients are managed with PCI, which usually includes a ...

Nuvelo Announces Positive Phase 1b Proof-of-Concept Data With Anticoagulant NU172

... and the ability to target protein-protein interactions. NU172 is an aptamer designed to directly inhibit thrombin's ability to stimulate blood clot formation in the setting of medical procedures where human blood is exposed to foreign materials. Specifically, NU172 is being studied for use as a ...

ViaViente Demonstrates Cardiovascular Benefits in New Human Trial

... in human metabolism. Thromboxane contributes to vasoconstriction, which can increase blood pressure, and platelet stickiness which can lead to clot formation. Both are associated with higher incidence of serious cardiovascular events. Reducing the production of thromboxane can help reduce ...

First U.S. Patient to Receive New Heart-Assist Device Doing Well After Surgery at University of Michigan

... National trial aims to help heart failure patients survive until transplant, and may offer lower clot risk and less blood damage than earlier heart devices ANN ARBOR, Mich., Aug. 5 /PRNewswire-USNewswire/ -- Anthony Shannon made history on July 30. ...

Advocate Christ Medical Center Using Glue-Like Liquid to Seal Off Brain Aneurysms

... has a wide neck separating it from the main blood vessel and to hold in place wire coils positioned inside the aneurysm. The wire coils facilitate clot formation, thereby stopping blood flow to the aneurysm and reducing the risk of rupture. Also in 2007, the same team, under Dr. Grobelny's ...

Nuvelo Initiates Phase 1B Clinical Trial of Anticoagulant NU172

... and the ability to target protein-protein interactions. NU172 is an aptamer designed to directly inhibit thrombin's ability to stimulate blood clot formation in the setting of medical procedures where human blood is exposed to foreign materials. Specifically, NU172 is being studied for use as a ...